


Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 204372000301	Application Number 09/300978
	Applicant Lynn E. SPITLER et al.	
	Filing Date April 28, 1999	Group Art Unit 1644
	Mailing Date March 2, 2000	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
M	1.	6/1976	3,960,827	Bjorklund	260	112R	_____
	2.	2/1983	4,372,945	Likhite	424	92	_____
	3.	5/1984	4,446,122	Chu <i>et al.</i>	424	1.1	_____
	4.	8/1984	4,468,457	Goldenberg <i>et al.</i>	435	69	_____
	5.	8/1987	4,689,222	McMichael	424	88	_____
	6.	10/1989	4,877,611	Cantrell	424	88	_____
	7.	10/1990	RE 33,405	Chu <i>et al.</i>	530	350	_____
	8.	10/1991	5,053,224	Koprowski <i>et al.</i>	424	85.8	_____
	9.	3/1993	5,262,177	Bystryn	434	240.2	_____
	10.	11/1993	5,262,177	Brown <i>et al.</i>	424	89	_____

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
M	11.	8/1991	WO 91/11465	WIPO	_____	_____	_____
	12.	6/1993	WO 93/10763	WIPO	_____	_____	_____
	13.	5/1994	WO 94/09820	WIPO	_____	_____	_____
	14.	1/1997	WO 97/03203	WIPO	_____	_____	_____
	15.	2/1998	WO 98/04727	WIPO	_____	_____	_____

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
M	16.	Ablin, "Immunotherapy for Prostatic Cancer: Previous and Prospective Considerations," ONCOLOGY (1975) 31:177-202
	17.	Alving, "Liposomes as Carriers of Antigens and Adjuvants" J IMMUNOL METHODS (1991) 140:1-13
	18.	Barth <i>et al.</i> , "Polyvalent Melanoma Cell Vaccine Induces Delayed-Type Hypersensitivity and in Vitro

EXAMINER: (examiner)

Gambler 10/10/00

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 204372000301	Application Number 09/300978
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Lynn E. SPITLER et al.	
		Filing Date April 28, 1999	Group Apt Unit 1644
		Mailing Date March 2, 2000	

O I P T E
 MAR 06 2000
 PATENT & TRADEMARK OFFICE

		Cellular Immune Response," CANCER RES (1994) 54:3342-3345
19.	Beckett <i>et al.</i> , "Monoclonal Antibody PD41 Recognizes an Antigen Restricted to Prostate Adenocarcinomas," CANCER RES (1991) 51:1326-1333	
20.	Berd <i>et al.</i> , "Autologous Hapten-Modified Melanoma Vaccine as Postsurgical Adjuvant Treatment After Resection of Nodal Metastases," J CLIN ONCOL (1997) 15(6):2359-2370	
21.	Berd <i>et al.</i> , "Treatment of Human Melanoma with a Hapten-Modified Autologus Vaccine," ANN NY ACAD SCI (1993) 690:147-152	
22.	Berd <i>et al.</i> , "Induction of Cell-Mediated Immunity to Autologous Melanoma Cells and Regression of Metastases after Treatment with a Melanoma Cell Vaccine Preceded by Cyclophosphamide," CANCER RES (198_) 46:2572-2577	
23.	Boring <i>et al.</i> , "Cancer Statistics," CA CANCER J CLIN (1993) 43:7-26	
24.	Bystryl, "Immunogenicity and Clinical Activity of a Polyvalent Melanoma Antigen Vaccine Prepared from Shed Antigens," ANN NY ACAD SCI (1993) 690:190-203	
25.	Bystryl <i>et al.</i> , "Relationship Between Immune Response to Melanoma Vaccine Immunization and Clinical Outcome in Stage II Malignant Melanoma," CANCER (1992) 69(5):1157-1164	
26.	Dai <i>et al.</i> , "Generation and Characterization of Monoclonal Anti-Idiotypic Antibodies for Dunning Rat Prostate Tumor," FASEB J (1988) Abstract No. 2301:A692	
27.	Deguchi <i>et al.</i> , "Effect of Methotrexate-Monoclonal Anti-Prostatic Acid Phosphatase Antibody Conjugate on Human Prostate Tumor," CANCER RES (1986) 46:3751-3755	
28.	Ezzell, "Cancer 'Vaccines': An Idea Whose Time Has Come," J NIH RESEARCH (1995) 7:46-49	
29.	Ghose <i>et al.</i> , "Antibody-Linked Cytotoxic Agents in the Treatment of Cancer: Current Status and Future Prospects," J NATL CANCER INST (1978) 61(3) 657-676	
30.	Hersey <i>et al.</i> , "Phase II Study of Vaccinia Melanoma Cell Lysates (VMCL) as Adjuvant to Surgical Treatment of Stage II Melanoma," CANCER IMMUNOL IMMUNOTHER (1986) 22:221-231	
31.	Hodge <i>et al.</i> , INT J CANCER (1995) 63:231-237	
32.	Hoover, Jr. <i>et al.</i> , "Biological Therapy of Cancer," Devita, Jr. <i>et al.</i> , BIOLOGIC THERAPY OF CANCER, eds. J.B. Lippincott Co. (1991) 670-701	
33.	Kantor <i>et al.</i> , "Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine," J NCI (1992) 84:1084-1091	
34.	Lee <i>et al.</i> , "Anti-Idiotypic Antibody for Dunning Rat Prostate Tumor," PROC AM ASSOC CANCER RES ANNU MEET (1988) Abstract No. 1005 29:253	
35.	Linehan, "Inhibition of Prostate Cancer Metastasis: A Critical Challenge Ahead," J NCI (1995) 87:331-332	
36.	McCune <i>et al.</i> , "Renal Cell Carcinoma Treated by Vaccines for Active Specific Immunotherapy: Correlation of Survival with Skin Testing by Autologous Tumor Cells," CANCER IMMUNOL	

EXAMINER: <i>GAM32</i> 10/10/02	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449		Docket Number 204372000301	Application Number 09/300978
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Lynn E. SPITLER et al.	
		Filing Date April 28, 1999	Group Art Unit 1644
		Mailing Date March 2, 2000	
		IMMUNOTHER (1990) 32(1):62-66	
PC	37.	Mitchell <i>et al.</i> , "Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates," ANN NY ACAD SCI (1993) 690:153-166	
	38.	Morton <i>et al.</i> , "Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanoma," ANN NY ACAD SCI (1993) 690:120-134	
	39.	Murphy <i>et al.</i> , "Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologous Dendritic Cells Pulsed with HLA-A0201-Specific Peptides from Prostate-Specific Membrane Antigen," THE PROSTATE (1996) 29:371-380	
	40.	Salgaller <i>et al.</i> , "Monitoring of Prostate-Specific Membrane Antigen (PSMA) - Restricted Responses in Patients Treated with Dendritic Cells Pulsed with PSMA - Derived Peptides," PROC AM ASSOC CANCER RES (1997) Abstract No. 4138 38:616	
	41.	Seigler <i>et al.</i> , "Melanoma Patient Antibody Responses to Melanoma Tumor-Associated Antigens Defined by Murine Monoclonal Antibodies," J BIOL RESPONSE MOD (1989) 8(1):37-52	
	42.	Spitler, "Cancer Vaccines: The Interferon Analogy," CANCER BIOTHERAPY (1995) 10:1-3	
	43.	Taneja <i>et al.</i> , "Construction of a Prostate Specific Antigen Promoter-Driven Gene Transfer Vector: A Novel Strategy for Target Specific Gene Therapy in Prostate Cancer," JOURNAL OF UROLOGY (1994) Abstract 151(5):491A	
	44.	Tsang <i>et al.</i> , "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes from Patients Immunized with Recombinant Vaccine," J NCI (1995) 87:982-990	
	45.	Vieweg <i>et al.</i> , "Immunotherapy Prostate Cancer in the Dunning Rat Model: Use of Cytosine Gene Modified Tumor Vaccines," CANCER RES (1994) 54:1760-1765	
	46.	Wallack <i>et al.</i> , "A Southeastern Cancer Study Group Phase I/II Trial with Vaccinia Melanoma Oncolysates," CANCER (1986) 57:649-655	
	47.	Watt <i>et al.</i> , "Human Prostate - Specific Antigen: Structural and Functional Similarity with Serine Proteases," PROC NATL ACAD SCI USA (1986) 83:3166-3170	
	48.	Wei <i>et al.</i> , "Expression of Human Prostate-Specific Antigen (PSA) in a Mouse Tumor Cell Line Reduces Tumorigenicity and Elicits PSA-Specific Cytotoxic T Lymphocytes," CANCER IMMUNOL IMMUNOTHER (1996) 42:362-368	
Re	49.	Wright, Jr. <i>et al.</i> , "A Novel Prostate Carcinoma-Associated Glycoprotein Complex (PAC) Recognized by Monoclonal Antibody TURP-27," INT J CANCER (1991) 47: 717-725	
EXAMINER: GAMBIZ 10/19/00			
DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			